CRI Cancer Immunotherapy Insights and Impact Report

The CRI Cancer Immunotherapy Insights and Impact report is a comprehensive analysis detailing the U.S. Food and Drug Administration (FDA) approvals in cancer immunotherapy from 2011 to the present. It outlines the evolution of immune-based therapies, which have transitioned from a new treatment option to a standard component of oncology care. The report documents over 150 distinct regulatory approvals, including immune checkpoint inhibitors, adoptive cell therapies, and novel immune-stimulatory agents. It highlights significant trends, such as the increase in FDA approvals, with 17 new therapies approved in 2024 alone. The report also discusses the diversification of treatment modalities and the growing accessibility of immunotherapies, including subcutaneous formulations. Additionally, it presents real-world data showing a more than 20-fold increase in the use of these therapies since 2011, indicating their rising prominence in cancer treatment. The report serves as an annual resource for understanding the trajectory of cancer immunotherapy and its implications for patient care.